Heart Failure Seminar: Focus on HFSA Scientific Statement on Cardio-Oncology and Heart Failure - OnDemand-HF Seminar - : Focus on HFSA Scientific Statement on Cardio-Oncology and Heart Failure (Video)

Video Transcription

Video Summary

In this comprehensive webinar hosted by the Heart Failure Society of America (HFSA) and led by Dr. Michelle Bloom and Anu Barak, a range of cases in cardio-oncology are discussed to explore the interaction between heart failure and cancer treatments. As the intersection of oncology and cardiology becomes more relevant, this session aimed to present practical cases highlighting challenges and considerations in managing patients with concurrent heart failure and cancer treatments.<br /><br />The webinar featured cases such as:<br />1. A patient with lung cancer experiencing EGFR tyrosine kinase inhibitor-induced cardiomyopathy, discussed by Dr. Dan Lenihan. Issues of optimal heart failure therapy and the importance of baseline cardiovascular assessment were emphasized.<br />2. A breast cancer patient developing heart failure due to HER2-targeted therapies. The focus was on personalized treatment adjustments and the concept of permissive toxicity.<br />3. A complex case of fulminant myocarditis associated with immunotherapy in metastatic prostate cancer, presented by Dr. Nick Palaskas. The session highlighted the use of immunomodulators and the challenges in implementing mechanical circulatory support.<br />4. The cardiovascular implications of Ibrutinib in a patient with chronic lymphocytic leukemia (CLL) were explored, emphasizing close monitoring for atrial fibrillation and heart failure, a concern increasingly recognized in long-term use.<br />5. A case tackling advanced heart failure therapies in a patient with recent breast cancer, led by Dr. Anju Nohria, brought attention to the timing and considerations of heart transplantation in cancer survivors.<br /><br />The session concluded by stressing the need for continuous research and collaborative guidelines to address the multifaceted challenges in cardio-oncology, given that traditional randomized trials may not always be feasible.

Keywords

cardio-oncology

heart failure

cancer treatments

EGFR tyrosine kinase inhibitor

HER2-targeted therapies

fulminant myocarditis

immunotherapy

Ibrutinib

chronic lymphocytic leukemia

atrial fibrillation

heart transplantation

collaborative guidelines